Phosphodiesterase inhibitor, selective for PDE3 (IC50 = 117 nM).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in DMSO|
Preparing Stock Solutions
The following data is based on the product molecular weight 284.32. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.52 mL||17.59 mL||35.17 mL|
|5 mM||0.7 mL||3.52 mL||7.03 mL|
|10 mM||0.35 mL||1.76 mL||3.52 mL|
|50 mM||0.07 mL||0.35 mL||0.7 mL|
References are publications that support the products' biological activity.
Freitag et al (1998) Phosphodiesterase inhibitors suppress α2-adrenoceptor-mediated 5-hydroxytryptamine release from trachea of newborn rabbits. Eur.J.Pharmacol. 354 67 PMID: 9726632
Tang et al (1994) Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Eur.J.Pharmacol. 268 105 PMID: 7925608
If you know of a relevant reference for Siguazodan, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Siguazodan, supplier, PDE3, inhibitors, inhibits, Phosphodiesterases, Phosphodiesterases, Phosphodiesterases, Tocris Bioscience
Citations for Siguazodan
Citations are publications that use Tocris products.
Currently there are no citations for Siguazodan. Do you know of a great paper that uses Siguazodan from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)